» Articles » PMID: 30701332

Quantitative DWI Predicts Event-free Survival in Children with Neuroblastic Tumours: Preliminary Findings from a Retrospective Cohort Study

Overview
Journal Eur Radiol Exp
Date 2019 Feb 1
PMID 30701332
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Quantitative diffusion-weighted imaging (DWI) probes into tissue microstructure in solid tumours. In this retrospective ethically approved study, we investigated DWI as a potential non-invasive predictor of tumour dignity and prognosis in paediatric patients with neuroblastic tumours.

Methods: Nineteen consecutive patients with neuroblastoma (NB, n = 15), ganglioneuroblastoma (GNB, n = 1) and ganglioneuroma (GN, n = 3) underwent 3-T magnetic resonance imaging at first diagnosis and after 3-month follow-up, following a protocol including DWI (b = 50 and 800 s/mm) in addition to standard sequences. All DWI scans were analysed for tumour volume assessment and apparent diffusion coefficient (ADC) calculation. Correlation with tumour pathology and risk factors (bone-marrow metastases, MYCN-amplification and 1p-deletion), therapeutic regime (observation versus chemotherapy) and clinical follow-up was evaluated.

Results: At baseline, mean ADC in NB was lower than in GNB/GN (0.76 vs. 1.47 × 10 mm/s, p = 0.003). An ADC cutoff ≤ 1.05 identified malignant disease with 100.0% sensitivity (95% confidence interval [CI] 29.2-100.0%) and 93.8% specificity (95% CI 69.8-99.8%). Initial ADC was < 0.80 in all NB patients with eventual tumour relapse. During follow-up, tumour ADC values increased in the observation group (NB/GN) without relapse (p = 0.043). In eventually relapsing tumours, ADC values at follow-up tended to decrease further despite reduction in tumour volume.

Conclusions: ADC values at first presentation differed significantly between malignant and benign neuroblastic tumours. Low baseline ADC was predictive of tumour progression and relapse in NB patients. With therapy, increasing ADC values appeared to predict relapse-free survival, while a decreasing ADC during therapy was an indicator of poor prognosis.

Citing Articles

Characterisation of Paediatric Neuroblastic Tumours by Quantitative Structural and Diffusion-Weighted MRI.

Tambasco D, Zlotnik M, Joshi S, Moineddin R, Harris S, Villani A J Clin Med. 2024; 13(22).

PMID: 39597804 PMC: 11594407. DOI: 10.3390/jcm13226660.


Quantitative MRI in Childhood Neuroblastoma: Beyond the Assessment of Image-defined Risk Factors.

Wang H, Cai J Radiol Imaging Cancer. 2024; 6(6):e240089.

PMID: 39485111 PMC: 11615636. DOI: 10.1148/rycan.240089.


Image-defined risk factors associated with MYCN oncogene amplification in neuroblastoma and their association with overall survival.

Wang H, Li T, Ni X, Chen X, He L, Cai J Abdom Radiol (NY). 2024; 49(6):1949-1960.

PMID: 38436700 DOI: 10.1007/s00261-024-04196-w.


Local MRI before and after Tumor Resection in Neuroblastoma: Impact of Residual Disease on Event Free Survival.

Schafer J, Gassenmaier S, Warmann S, Urla C, Frauenfeld L, Flaadt T J Clin Med. 2023; 12(23).

PMID: 38068349 PMC: 10707530. DOI: 10.3390/jcm12237297.


Combined Metabolic and Functional Tumor Volumes on [F]FDG-PET/MRI in Neuroblastoma Using Voxel-Wise Analysis.

Chaika M, Mannlin S, Gassenmaier S, Tsiflikas I, Dittmann H, Flaadt T J Clin Med. 2023; 12(18).

PMID: 37762918 PMC: 10531552. DOI: 10.3390/jcm12185976.


References
1.
Lonergan G, Schwab C, Suarez E, Carlson C . Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: radiologic-pathologic correlation. Radiographics. 2002; 22(4):911-34. DOI: 10.1148/radiographics.22.4.g02jl15911. View

2.
Uhl M, Altehoefer C, Kontny U, Ilyasov K, Buchert M, Langer M . MRI-diffusion imaging of neuroblastomas: first results and correlation to histology. Eur Radiol. 2002; 12(9):2335-8. DOI: 10.1007/s00330-002-1310-9. View

3.
Spix C, Pastore G, Sankila R, Stiller C, Steliarova-Foucher E . Neuroblastoma incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006; 42(13):2081-91. DOI: 10.1016/j.ejca.2006.05.008. View

4.
Koh D, Collins D . Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol. 2007; 188(6):1622-35. DOI: 10.2214/AJR.06.1403. View

5.
Gahr N, Darge K, Hahn G, Kreher B, von Buiren M, Uhl M . Diffusion-weighted MRI for differentiation of neuroblastoma and ganglioneuroblastoma/ganglioneuroma. Eur J Radiol. 2010; 79(3):443-6. DOI: 10.1016/j.ejrad.2010.04.005. View